Skip to main content
SpringerLink
Log in

Controlled trials on the effects of prostacyclin in vascular disease

  • Chapter
IUPHAR 9th International Congress of Pharmacology London 1984

  • 106 Accesses

Abstract

Prostacyclin (PGI2) is now available for intravascular infusions as a stable freeze-dried preparation under the approved name of epoprostenol and the trade names of Flolan (Wellcome) and Cycloprostin (Up-john). Vasodilatory and platelet-suppressant activities of prostacyclin in vitro which had been described at the time of its discovery (Moncada et al., 1976) were reproduced in healthy volunteers (Szczeklik et al., 1978b; Gryglewski et al., 1978). Those two properties of prostacyclin constitute a basic rationale for its clinical use in vascular disease, although stimulation of the fibrinolytic system by prostacyclin in man (Dembińska-Kieć et al., 1982; Szczeklik et al., 1983) and its cytoprotective action in animals (for references see Vane, 1983; Sikujara et al., 1983; Whittle &; Moncada, 1983) require a careful consideration in further clinical trials

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • ASSAL, A.W., HELG, C. &;amp; VONDERWELD, N. (1980). Prostacyclin perfusions in diabetic peripheral arterial insufficiency. Diabetologia, 19, 254.

    Google Scholar 

  • BELCH, J.J.F., DRURY, J.K., CAPELL, H., FORBES, CH.D., NEWMAN, P., Mckenzie, F., LEIBERMAN, P. & PRENTICE, C.R.M. (1983a). Intenmittent epoprostenol (prostacyclin) infusion in patients with Raynaud’s syndrome. Lancet, i, 313–315.

    Article  Google Scholar 

  • BELCH, J.J.F., McARDLE, B., POLLOCK, J.G., FORBES, CH.D., McKAY, A., LEIBERMAN, P., LOWE, G.D. & PRENTICE, C.R.M. (1983b). Epoprostenol (prostacyclin) and severe arterial disease. Lancet, i, 315–317.

    Article  Google Scholar 

  • BELCH, J.J.F., NEWMAN, P., DRURY, J.K., CAPELL, H., LEIBERMAN, P., JAMES, W.B., FORBES, C.D. & PRENTICE, C.R.M. (1981). Successful treatment of Raynaud’s syndrome with prostacyclin. Thromb. Haemostas., 44, 255–256.

    Google Scholar 

  • BERGMAN, G., DALY, K., ATKINSON, L., ROTHMAN, M., RICHARDSON, P. J., JACKSON, G. & JEWITT, D.E. (1981). Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease. Lancet, i, 596.

    Google Scholar 

  • BRANDT, R., DEMBIŃSKA-KIEĆ, A., KORBUT, R., GRYGLEWSKI, R.J. & NOWAK, J. (1984). Release of prostacyclin from human pulmonary vascular bed in response to cholinergic stimulation. Naunyn-Schmiedeberg’s Arch. Pharmac., 325, 69–75.

    Article  CAS  Google Scholar 

  • BUNTING, S., MONCADA, S. & VANE, J.R. (1983). The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications. Br. med. Bull., 39, 271–276.

    PubMed  CAS  Google Scholar 

  • CHIERCHIA, S., PATRONO, C., CIABATFONI, G., DE CATERINA, R., CINOTTI, G.A., DISTANTE, A. & MASERI, A. (1982). Effect of intravenous prostacyclin in variant angina. Circulation, 65, 470–477.

    Article  PubMed  CAS  Google Scholar 

  • DECKMYN, H., VANHOUTTE, E., VERSTRAETE, M. & VERMYLEN, J. (1983). Manipulation of the local thromboxane and prostacyclin balance in vivo by the anti-thrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. Biochem. Pharmac., 32, 2757–2762.

    Article  CAS  Google Scholar 

  • DEMBIŃSKA-KIEĆ, A., KORBUT, R., BIEROŃ, K., KOSTKA-TRĄBKA, E. & GRYGLEWSKI, R.J. (1983). Beta-Pyridylcarbinol (Ronicol) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans. Pharmac. Res. Commun., 15, 377–385.

    Article  Google Scholar 

  • DEMBIŃSKA-KIEĆ, A., KOSTKA-TRĄBKA, E. & GRYGLEWSKI, R.J. (1982). Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans. Thromb. Haemostas., 47, 190.

    Google Scholar 

  • DEMBIIVSKA-KIE6, A., ZMUDA, A., GRODZINSKA, L., BIERON, K., BASISTA, M., KEDZIOR, A., KOSTKATRABKA, E., TELESZ, E. & ZELAZNY, T. (1981). Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins, 21, 827–831.

    Article  PubMed  Google Scholar 

  • EDHAG, O., HENRIKSSON, P. & WENNMALM, A. (1983). Prostacyclin infusion in patients with acute myocardial infarction (preliminary report). New Engl. J. Med., 308, 1032–1033.

    PubMed  CAS  Google Scholar 

  • FISCHER, S. & WEBER, P.C. (1984). Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature, 307, 165–168.

    Article  PubMed  CAS  Google Scholar 

  • FOX, K.H., JONATHAN, A. & SELVYN, A.P. (1982). Effect of platelet inhibition on myocardial ischaemia. Lancet, ii, 727–730.

    Article  Google Scholar 

  • GRYGLEWSKI, R.J. (1982). In Advances in Pharmacology and Therapeutics II, Vol. 4. Yoshida, H., Hagihara, Y. & Ebashi, S. (eds) pp. 235–250, Oxford/New York: Pergamon Press.

    Google Scholar 

  • GRYGLEWSKI, R.J., NOWAK, S., KOSTKA-TRĄBKA, E., KUŚMIDERSKI, J., DEMBIŃSKA-KIE-, A., BIROŃ, K., BASISTA, M. & BLASZCZYK, B. (1983). Treatment of ischaemic stroke with prostacyclin. Stroke, 14, 197–202.

    Article  PubMed  CAS  Google Scholar 

  • GRYGLEWSKI, R.J., RADOMSKI, M., ŚWIĘS, J. & OCETKIEWICZ, A. (1982). In Role of Chemical Mediators in the Pathophysiology of Acute Illness and Injury. Rita McConn (ed.) pp. 253–262, New York: Raven Press.

    Google Scholar 

  • GRYGLEWSKI, R.J. & SZCZEKLIK, A. (1984). In Thrombosis and Cardiovascular Disease. Advances in Experimental Medicine and Biology, Vol. 164. Strano, A. (ed.) pp. 211–214, New York/London: Plenum Press.

    Chapter  Google Scholar 

  • GRYGLEWSKI, R.J., SZCZEKLIK, A. & NIŻANKOWSKI, R. (1978). Anti-platelet effects of intravenous infusion of prostacyclin in man. Thromb. Res., 13, 153–163.

    Article  PubMed  CAS  Google Scholar 

  • GUADAGNI, D.N., IKRAM, H. & MASLOWSKI, R. (1981). Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension. Br. Heart J., 45, 385–388.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • HALL, R.J. & DEWAR, H.A. (1981). Safety of coronary arterial prostacyclin infusion (Letter). Lancet, i, 949.

    Article  Google Scholar 

  • HALLENBECK, J.M. (1984). In Prostacyclin. Clinical Trials. Gryglewski, R.J., McGiff, J.C. & Szczeklik, A. (eds), New York: Raven Press (in press).

    Google Scholar 

  • HENRIKSSON, P., EDHAG, O. & WENNMALM, A. (1984). In Prostacyclin. Clinical Trials, Gryglewski, R.J., McGiff, J.C. & Szcezeklik, A. (eds) New York: Raven Press (in press).

    Google Scholar 

  • HOSSMAN, V., HEINEN, A. & AUEL, H. (1981). A randomized placebo-controlled trial of prostacyclin (PGI2) in peripheral arterial disease. Thromb. Res., 22, 481–490.

    Article  PubMed  CAS  Google Scholar 

  • HUCZYŃSKI, J., KOSTKA-TĄBKA, E., SOTOWSKA, W., BIEROŃ, K., GRODZIŃSKA, L., DEMBIŃSKA-KIEĆ, A., PAKOSZ-MAZUR, E., PĘZAK, E. & GRYGLEWSKI, R.J. (1984). In Prostacychn. Clinical Trials, Gryglewski, R.J., McGiff, J.C. & Szczeklik, A. (eds), New York: Raven Press (in press).

    Google Scholar 

  • KADOWITZ, P.J., SPANNHAKE, E.W., LEVIN, J.L. & HYMAN, A.L. (1980). In Advances in Prostaglandin and Thromboxane Research. Samuelsson, B., Ramwell, P.W. & Paoletti, R. (eds) pp. 731–743, New York: Raven Press.

    Google Scholar 

  • KAUKINEN, S., PESSI, T., YLITALO, P., KRAIS, T. & VAPAATALO, H. (1984). In Prostacyclin. Clinical Trials, Gryglewski, R.J., McGiff, J.C. & Szczeklik, A. (eds) New York: Raven Press (in press).

    Google Scholar 

  • LEITHNER, C., SINZINGER, H. & SCHWARTZ, M. (1981). Treatment of chronic kidney transplant rejection with prostacyclin — reduction of platelet deposition in the transplant; prolongation of platelet survival and improvement of transplant function. Prostaglandins, 22, 783–788.

    Article  PubMed  CAS  Google Scholar 

  • LEWIS, P.J. & DOLLERY, C.T. (1983). Clinical pharmacology and potential of prostacyclin. Br. med. Bull., 39, 281–284.

    PubMed  CAS  Google Scholar 

  • MACHIN, S.J., DEFREYN, G., CHAMONE, D.A. & VERMYLEN, J. (1981). In Clinical Pharmacology of Prostacyclin, Lewis, P.J. & O’Grady, J.M. (eds) p. 173, New York: Raven Press.

    Google Scholar 

  • MARTIN, J.F., HANDY, N.A.T., NICHOLL, J., LEWATAS, N., BERGVALL, U., OWEN, P., WHITTINGTON, D. & HOLRYHOD, M. (1984). In Prostacyclin. Clinical Trials. Gryglewski, R.J., McGiff, J.C. & Szczeklik, A. (eds), New York: Raven Press (in press).

    Google Scholar 

  • MEISTER, W., VON SCHAKY, C., WEBER, M., LORENZ, R., KOTZUR, J., REICHART, B., THEISEN, K. & WEBER, P.C. (1984). Low-dose acetylsalicylic acid (100mg/day) after aortocoronary bypass surgery: a placebocontrolled trial. Br. J. clin. Pharmac., 17, 703–711.

    Article  CAS  Google Scholar 

  • MITCHELL, J.R.A. (1983). Clinical aspects of the arachidonic acid — thromboxane pathway. Br. med. Bull., 39, 289–295.

    PubMed  CAS  Google Scholar 

  • MONCADA, S., GRYGLEWSKI, R.J., BUNTING, S. & VANE, J.R. (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 263, 663–665.

    Article  PubMed  CAS  Google Scholar 

  • NERI SERNERI, G.G. (1982). In Cardiovascular Pharmacology of the Prostaglandins, Herman, A.G., VanHoutte, P.M., Denolin H. & Goosens, A. (eds) pp. 361–374, New York: Raven Press.

    Google Scholar 

  • NIADA, R., MANTOVANI, M., PRINO, G., PESCADOR, R., PORTA, R., BERTI, F., FOLCO, G.C., OMINI, C. & VIGANO, T. (1982). PGT2-generation and antithrombotic activity of orally administered defibrotide. Pharmac. Res. Commun., 14. 949–957.

    Article  CAS  Google Scholar 

  • NIŻANKOWSKI, R., KRÓLIKOWSKI, W., BIELATOWICZ, J., SCHALLER, J. & SZCZEKLIK, A. (1984). In Prostacyclin. Clinical Trials, Gryglewski, R.J., McGiff, J.C. & Szczeklik, A. (eds), New York: Raven Press (in press).

    Google Scholar 

  • OLSSON, A.G. (1980). Intravenous prostacyclin for ischaemic ulcers in peripheral artery disease (Letter). Lancet, ii, 1076.

    Article  Google Scholar 

  • OLSSON, A.G. (1984). InAtherosclerosis, Miller, N.E. (ed.) pp. 91–104, New York: Raven Press.

    Google Scholar 

  • OLSZEWSKI, E., SEKUŁA, J., KOSTKA-TRĄBKA, E., GRODZIŃSKA, L., DEMBIŃSKA-KIEĆ, A., BIEROŃ, K., BASISTA, M., KĘDZIOR, A. & GRYGLEWSKI, R.J. (1984). In Prostacyclin. Clinical Trials. Gryglewski, R.J., McGiff, J.C. & Szczeklik, A. (eds) New York: Raven Press (in press).

    Google Scholar 

  • PARDY, B.J., LEWIS, J.D. & EASTCOTF, H.H.G. (1981). Preliminary experience with prostaglandin E1 and I2 in peripheral vascular disease. Surgery, 88, 826–832.

    Google Scholar 

  • PICKLES, H. & O’GRADY, J. (1982). Side-effects occurring during administration of epoprostenol (prostacyclin, PGI2) in man. Br. J. clin. Pharmac., 14, 177–185.

    Article  CAS  Google Scholar 

  • PRENTICE, C.R.M. & BELCH, J.J.F. (1984). In Prostacyclin. Clinical Trials, Gryglewski, R.J., McGiff, JC. & Szczeklik, A. (eds) New York: Raven Press (in press).

    Google Scholar 

  • PRENTICE, C.R.M., BELCH, J.J.F., McKAY, A., McARDLE, B., LEIBERMAN, P., POLLOCK, J.G., LOWE, G.D.O. & FORBES, C.D. (1984). In Prostacyclin. Clinical Trials, Gryglewski, R.J., McGiff, J.C. & Szczeklik, A. (eds) New York: Raven Press (in press).

    Google Scholar 

  • RHODES, R.S. & HEARD, S.E. (1983). Detrimental effect of high-dose prostaglandin E1 in the treatment of ischaemic ulcers. Surgery, 93, 839–842.

    PubMed  CAS  Google Scholar 

  • RUBIN, L.J., GROVES, B.M., REEVES, J.Y., FROSOLONO, M., HENDEL, F. & CATO, A. (1982). Prostacyclininduced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation, 66, 334–338.

    Article  PubMed  CAS  Google Scholar 

  • SCHOLKENS, B.A., GEHRING, D. & JUNG, W. (1983). The orally-active thia-imino-prostacyclin HOW 892: antiaggregatory and cardiovascular activities. Prostaglandins, Leukotrienes and Medicine, 10, 231–256.

    Article  CAS  Google Scholar 

  • SIKUJARA, O., MONDEN, H., TOYOSHIMA, K., OKAMURA, J. & KOSAKI, G. (1983). Cytoprotective effect of prostaglandin I2 on ischemia-induced hepatic cell injury. Transplantation, 36, 238–243.

    Article  PubMed  CAS  Google Scholar 

  • SINZINGER, H, O’GRADY, J., CROMWELL, M. & HOFER, R. (1983). Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic grafts. Lancet, i, 1275–1276.

    Article  Google Scholar 

  • SINZINGER, H., SILBERBAUER, K., HARSCH, A.K. & GALL, A. (1981). Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease - a rebound phenomenon. Prostaglandins, 21, 49–51.

    Article  PubMed  CAS  Google Scholar 

  • SRIVASTAVA, K.C. & AWASHTI, K.K. (1983). Effects of labetalol on the arachidonic acid metabolism in human blood platelets and in lung and aorta of the rat. Prostaglandins, Leukotrienes and Medicine, 12, 1–9.

    Article  CAS  Google Scholar 

  • SZCZEKLIK, A., GRYGLEWSKI, R.J., MUSIAL, J., GRODZINSKA, L., SERWOŃSKA, M. & MARCINKIEWICZ, E. (1978a). Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb. Haemostas., 40, 66–74.

    CAS  Google Scholar 

  • SZCZEKLIK, A., GRYGLEWSKI, R.J., NIŻANKOWSKI, R., MUSIAŁ, J., PIETOŃ, R. & MRUK, J. (1978b). Circulatory and antiplatelet effects of intravenous prostacyclin in healthy men. Pharmac. Res. Commun.,10, 545–556.

    Article  CAS  Google Scholar 

  • SZCZEKLIK, A., KOPEĆ, M., SŁADEK, K., MUSIAŁ, J., CHMIELEWSKA, J., TEISSEYRE, E., DUDEKWOJCIECHOWSKA, G. & PALESTER-CHLEBOWCZYK, M. (19830. Prostacyclin and the fibrinolytic system in ischemic vascular disease. Thromb. Res., 29, 655-b60.

    Google Scholar 

  • SZCZEKLIK, A., NIŻANKOWSKI, R., SKAWIŃSKI, S., SZCZEKLIK, J., GLUSZKO, P. & GRYGLEWSKI, R.J. (1979). Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet, i, 1111–1114.

    Google Scholar 

  • SZCZEKLIK, A., NIZANKOWSKI, R., SZCZEKLIK, J., TABEAU, J. & KRÓLIKOWSKI, W. (1984). In Prostacyclin. Clinical Trials. Gryglewski, R.J., McGiff, J.C. & Szczeklik, A. (eds), New York: Raven Press (in press).

    Google Scholar 

  • SZCZEKLIK, J., SZCZEKLIK, A. & NIŻANKOWSKI, R. (1980). Prostacyclin for pulmonary hypertension (Letter). Lancet, ii, 1076.

    Google Scholar 

  • SZCZEKLIK, A., SZCZEKLIK, J. & NIŻANKOWSKI, R. (1981). Prostacyclin, nitroglycerin and effort angina (Letter). Lancet, i, 1006.

    Google Scholar 

  • UCHIDA, Y., HANAI, T., HASEGAWA, K., KAWAMURA, K. & OSHIMA, T. (1982). Coronary recanalization induced by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Circulation, 66 (part II) abstr. No 1045.

    Article  Google Scholar 

  • VANE, J.R. (1983). Prostaglandins and the cardiovascular system. Br. Heart J., 49, 405–409.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • WARSO, M.A. & LANDS, W.E.M. (1983). Lipid peroxidation in relation to prostacyclin and thromboxane physiology and pathophysiology. Br. med. Bull., 39, 277–280.

    PubMed  CAS  Google Scholar 

  • WATKINS, W.D., PETERSON, M.B., CRONE, R.K., SHANDON, D.C. & LEVIVE, L. (1980). Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension (Letter). Lancet, i, 1083.

    Article  Google Scholar 

  • WEKSLER, B.B., PETT, S.B., ALONSO, D., RICHTER, R., STELZER, C., SUBRAMANIAN, V., TACK-GOLDMAN, K. & GAY, W.A., Jr. (1983). Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. New Engl. J. Med., 308, 800–805.

    Article  PubMed  CAS  Google Scholar 

  • WHITTLE, B.J.R. & MONCADA, S. (1983). Pharmacological interactions between prostacyclin and thromboxanes. Br. med. Bull., 39, 232–238.

    PubMed  CAS  Google Scholar 

  • YUI, Y., NAKAJIMA, H., KAWAI, C. & MURAKAMI, T. (1982). Prostacyclin therapy in patients with congestive heart failure. Am. J. Cardiol., 50, 320–324.

    Article  PubMed  CAS  Google Scholar 

  • ZEHAVI, J., HAMILTON, W.A.P., O’REILLEY, M.Y.G., LEYTON, J., COTTON, L.T. & KAKKAR, V.V. (1980). Plasma exchange and platelet function in Raynaud’s phenomenon. Thromb. Res., 19, 86–93.

    Google Scholar 

  • ŻYGULSKA-MACH, H., KOSTKA-TRABKA, E., GRODZIŃSKA, L. BIEROŃ, K., TELESZ, E. & GRYGLEWSKI, R.J. (1984). In Prostacyclin. Clinical Trials, Gryglewski, R.J., McGiff, J.C. & Szczeklik, A. (eds) New York: Raven Press (in press).

    Google Scholar 

  • ŻYGULSKA-MACH, H., KOSTIKA-TRABKA, E., NTTOŃ, A. & GRYGLEWSKI, R.J. (1980). Prostacyclin in central retinal vein occlusion (Letter). Lancet, ii, 1075.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Copernicus Academy of Medicine in Cracow, 16, Grzegórzecka, 31-531, Cracow, Poland

    R. J. Gryglewski

Authors
  1. R. J. Gryglewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

William Paton James Mitchell Paul Turner Cheryl Padgham Eileen Ashcroft

Copyright information

© 1984 Macmillan Publishers Limited

About this chapter

Cite this chapter

Gryglewski, R.J. (1984). Controlled trials on the effects of prostacyclin in vascular disease. In: Paton, W., Mitchell, J., Turner, P., Padgham, C., Ashcroft, E. (eds) IUPHAR 9th International Congress of Pharmacology London 1984. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-17615-1_5

Download citation

Publish with us

Policies and ethics

Search

Navigation